IVD的世界市场趋势(2023年3月)

IVD Market Trends Report, March 2023

出版日期: 2023年03月17日 | 出版商:

Kalorama Information | 英文 56 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

本报告提供全球IVD市场相关调查分析，促进市场成长的要素与趋势，COVID-19的影响，产品趋势与新发展等彙整资讯。

Diagnostic testing continues to be a valuable resource to help physicians arrive at a diagnosis. Additionally, it has gone from helping the physician to diagnose illness to providing the physician with invaluable information on treatments such as precision medicine. Now, in the aftermath of the COVID-19 pandemic, new products, changes in global health spending, regulatory changes in major markets and disease trends are among the factors that produce a constantly changing market picture but one that remains resilient. Ultimately, the IVD market remains dynamic, demonstrating constant innovations.

In “IVD Market Trends Report, March 2023 ”, Kalorama Information analyses and answers:

What's Driving Growth in the IVD Market since Q1 2022 and into Q1 2023?

What Major Trends have been Affecting the Market since Q1 2022 and into Q1 2023?

How Has COVID-19 Impacted and Continued to Impact the Market?

What Product Trends and New Developments Will Shape the IVD Market?

Kalorama Information continues to be diligent in outlining the IVD market and its rapidly changing landscape. Kalorama Information has been and continues to be superior in accessing the market due to the extensive experience of its analysts and commitment by the company to present the most accurate data available.

Chapter 1: Worldwide IVD Market - March 2023 Update

IVD Market Demand and Growth
- Figure 1-1: Quarter-by-Quarter Segment Performance Commentary, 2022
- Table 1-1: Global In Vitro Diagnostic Sales by Product Market, 2022 ($ million) (Clinical Chemistry; Immunoassays: Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c - lab; Hematology - Core Lab; Microbiology (ID/AST); Microbiology (molecular); Microbiology - Mass Spectrometry; Coagulation (PT/INR); Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular - NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry; Other IVD)
- Figure 1-2: IVD Segment Performance (Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other), Q1 2022 - Q4 2022 ($MN)
- Figure 1-3: IVD Segment Performance (Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other), Total Market Value, 2022 ($MN)
COVID-19 Diagnostic Markets
- Table 1-2: COVID-19 Product Sales - Immunoassay (Antigen, Serology), Molecular, Rapid - 2022 ($ millions)
Effect of COVID-19 on Market Segments
- Table 1-3: IVD Market excluding and with COVID-19, 2022
- Figure 1-4: IVD Market Distribution by Segment (COVID-19 Assays and Instruments, IVD Market excluding COVID-19 Assays and Instruments), 2022
- Figure 1-5: IVD Market by COVID-19 and non-COVID markets, Quarterly Performance, 2022
- Table 1-4: Global In Vitro Diagnostic Market - YoY Growth 2021-2022
- Figure 1-6: Global In Vitro Diagnostic Market - YoY Growth, by Segment (Blood Bank Molecular - NAT Screens, Blood Grouping/Typing, Clinical Chemistry, Coagulation (PT/INR), D-Dimer, Diabetes HbA1c lab, Drugs of Abuse, Hematology - Core Lab, Histology/Cytology, Immuno - Blood Bank Screening, Immuno - Infectious Disease, Microbiology (ID/AST), Microbiology (Molecular), Nucleic Acid Assays/genetic Tests, Other Immunos, POC - OTC Diabetes, POC - OTC Other, POC - Professional/Hospital), 2021-2022

Chapter 2: Product Trends and New Developments

Selected New - Q4 2022 and Q1 2023 - Core IVD Product Launches, Developments and Trends
Immunoassay
Molecular
Personalized Medicine
POC
Sequencing
Selected COVID-19 Developments - Q4 2022 - Q1 2023
- Figure 2-1: COVID-19 Test Market by Type, Q1-Q4 2022 - COVID-19 Testing Wanes
Antigen/Antibody
Molecular

Chapter 3: Top IVD Market Participant Results

Selected Competitive Leader Updates
- Figure 3-1: IVD Segment Growth by Leading Competitors (Abbott Diagnostics, Becton Dickinson, bioMerieux, Danaher, Hologic, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific), Change in Sales, 2021-2022
- Figure 3-2: Changes in Market Distribution for IVD Sales, 2019-2022 - Roche and Abbott Battle for #1 Spot
- Figure 3-3: Comparison of Total Diagnostic Sales for Abbott vs Roche 2020-2022 (in millions $)
2022 M&A Activity
- Table 3-1: IVD-Relevant M&A Activity, 2022
- Figure 3-4: Count of IVD Industry M&A Deals by Month, Full Year 2022 and Jan-Feb 2023
Abbott Laboratories
- Table 3-2: Abbott Corporate Summary
- Figure 3-5: Abbott Diagnostics Revenue by Segment (Core Laboratory, Molecular, Point-of-Care, Rapid Diagnostics, COVID-19), Full Year 2021 and 2022 $M
Becton Dickinson and Co
- Table 3-3: Becton Dickinson Corporate Summary
- Figure 3-6: BD Life Sciences, Revenues by Business FY End September 30, 2021, and 2022 $M
bioMerieux SA
- Table 3-4: bioMerieux Corporate Summary
- Figure 3-7: bioMerieux Clinical Applications Segment, Full Year Results, 2021, 2022 € MN
Danaher Corporation
- Table 3-5: Danaher Corporation Summary
- Figure 3-8: Danaher Diagnostic Segment Performance, Full Year Results, 2021 ,2022 $M
Hologic, Inc.
- Table 3-6: Hologic Corporate Summary
- Figure 3-9: Hologic Diagnostic Segment Performance, Full Year Results, FY 2021 and FY 2022, $M
QuidelOrtho Corporation
- Table 3-7: QuidelOrtho Corporate Summary
- Figure 3-10: QuidelOrtho, Full Year Results, by Segment (Immunoassay/Clinical Lab, Molecular Diagnostics, Point-of-Care, Transfusion Medicine) $M (2021, 2022)
Roche Diagnostic
- Table 3-8: Roche Diagnostic Corporate Summary
- Figure 3-11: Roche Diagnostics Revenue by Product Group (Core Lab, Diabetes Care, Molecular, Pathology Lab, Point-of-Care), Full Year Results 2021, 2022, CHF MN
Siemens Healthineers
- Table 3-9: Siemens Healthineers Corporate Summary
- Figure 3-12: Siemens Diagnostics Revenue, FY 2021 and FY 2022, € MN
Sysmex Corporation
- Table 3-10: Sysmex Corporate Summary
- Figure 3-13: Sysmex Revenue by Product Segment (Clinical Chemistry, FCM, Hematology, Hemostasis, Immunochemistry, Urinalysis, Others), FY 2021, 2022 and 2023, JPY MN
Thermo Fisher Scientific
- Table 3-11: Thermo Fisher Scientific Corporate Summary
- Figure 3-14: Thermo Fisher Scientific COVID-19 Response Revenue, 2021 and 2022, by Quarter $B